Covi-Pantel . NZ Trader Release, page-1421

Jakjazz, work on Albendazole has been discontinued as to Anti-mucin I don't know.

So to my knowledge MPL and Epichem are the two things of value that remain on that table.

Epichem is gaining traction and proving to be an asset to PAA with the Waist to Fuel project and the other stuff they have going on.

There has been a lot of water pass under the bridge since 2015, back then MPL was seen as a possible treatment for a couple of human cancers and cancer in dogs. The patent on MPL was also firmly held by other party's.

Although the Monepantel patent is currently held by Elanco their patents start to run out next year. In the time since 2015 our BoD have secured world patents on MPL for the use on many cancers, neurodegenerative diseases and just lately COVID until at least 2033.

A quick search will reveal what is spent p.a. on these ailments. I believe the 100mill number is well under value. I agree with your statement.
Continued success of MPL would mean the SP has no upper limit so gotta continue to hang in there to reap the future benefit